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PDE5a is a cGMP-selective phosphodiesterase that has
been known to play a particularly important role in cGMP
regulation within vascular smooth muscle of the corpus
cavernosum and pulmonary vessels. Its involvement in
cardiac muscle regulation has been previously considered
minimal, in part due to low expression levels and the lack
of change in basal heart function in response to selective
PDE5a inhibition. However, PDE5a expression in cardiac
myocytes appears localized (at z-bands) and confers tar-
geted regulation of stress responses despite having little
influence on basal function. In both intact hearts and iso-
lated myocytes, PDE5a inhibition enhances cGK-1 activa-
tion and counters beta-adrenergic stimulated contractility.
This effect depends upon the presence of NOS-3 activity,
as both mice genetically lacking NOS3 and those with
NOS inhibited pharmacologically do not display func-
tional changes with PDE5a inhibition. The role of NOS3
appears specific, as alternative sources of cGMP (i.e. medi-
ated by natriuretic peptides) do not appear to provide
cGMP in the right compartment to influence PDE5a regu-
latory effects. Chronic isoproterenol stimulation (two
weeks delivered by osmotic pump) of C57Bl6 mice results
in cardiac hypertrophy and fibrosis. This is markedly
inhibited by co-administration of a PDE5a inhibitor. Mice
genetically lacking NOS3 also develop hypertrophy, but
this is not affected by PDE5a inhibition. Similar results
have been obtained using another hormonal stimulant of
hypertrophy – angiotensin II.
A more comprehensive stress that stimulates both cardiac
hypertrophy and pathological remodelling is pressure
overload. Mice exposed to chronic trans-aortic constric-
tion develop marked LVH and chamber dilation. Co-treat-
ment with sildenafil (at doses yielding clinically relevant
plasma concentrations) suppresses both hypertrophy and
fibrosis while improving cardiac systolic and diastolic
function, despite sustained pressure load. Sildenafil can
also be administered after hypertrophy has been estab-
lished and reverse it. While chronic PDE5a inhibition has
negligible impact on cGK-1 activation in the unstressed
heart, this is changed in the hypertrophied ventricle,
where the contribution of PDE5A to total cGMP esterase
activity nearly doubles, and PDE5A inhibition results in
marked increases in cGK-1 activity. Suppression of hyper-
trophy is coupled to inhibition of multiple signaling-
pathways (calcineurin-NFAT, PI3K-Akt, and ERK1/2), and
appears to involve multiple targeted interactions. Addi-
tional pathways that appear involved are the STAT-3 path-
way, and RhoA-RhoK pathway. Whether the anti-
hypertrophic effect is due related to a single primary or
multiple targets, whether factors other than cGK-1 medi-
ate the effects from PDE5a inhibition, and how PDE5a is
localized remain the focus of ongoing investigations.
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